Octavie Lunguya

Octavie Lunguya

Auto-generated profile, based on publicly available information

Octavie Lunguya

Department of Microbiology, Institut National de Recherche Biomédicale , Kinshasa

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2025 in Clinical Infectious Diseases
Verified
Journal Article
Open access
CKCara Lynn Kim
Cara Lynn Kim
TTThaint Thaint Thwe
Thaint Thaint Thwe
LELigia M Cruz Espinoza
Ligia M Cruz Espinoza
JSJonathan D Sugimoto
Jonathan D Sugimoto
MFMosoka P Fallah
Mosoka P Fallah
BTBirkneh Tilahun Tadesse
Birkneh Tilahun Tadesse
Before the onset of the coronavirus disease 2019 (COVID-19) pandemic, the African region already faced a substantial communicable disease burden and a rising prevalence of noncommunicable and chronic conditions. The COVID-19 pandemic has underscored critical vulnerabilities within the health systems in African countries and highlighted the urgent need for self-sufficiency to increase resilience in vaccine manufacturing and clinical trial capacity. In response, substantial efforts are underway to develop vaccine and pharmaceutical manufacturing capabilities across the continent. Ongoing initiatives supported by large donor organizations are aimed at initiating much-needed progress toward greater self-sufficiency in vaccine production in Africa, as coordinated by the Africa Centers for Disease Control. Continued investment, regulatory harmonization, and strengthened international and regional partnerships are essential for Africa to develop sustainable vaccine manufacturing.

1 February 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
PBPatrick Musole Bugeme
Patrick Musole Bugeme
HXHanmeng Xu
Hanmeng Xu
CHChloe Hutchins
Chloe Hutchins
JDJuan Dent
Juan Dent
JSJaime Mufitini Saidi
Jaime Mufitini Saidi
EMEspoir Bwenge Malembaka
Espoir Bwenge Malembaka
Our understanding of the burden and drivers of cholera mortality is hampered by limited surveillance and confirmation capacity. Leveraging enhanced clinical and laboratory surveillance in the cholera-endemic community of Uvira, eastern Democratic Republic of Congo, we describe cholera deaths across 3 epidemics between September 2021 and September 2023 following mass vaccination.

7 December 2022 in Transfusion
Verified
Journal Article
Closed access
AHAnne-Sophie Heroes
Anne-Sophie Heroes
POPatient Okitale
Patient Okitale
NNNatacha Ndalingosu
Natacha Ndalingosu
PVPhilippe Vandekerckhove
Philippe Vandekerckhove
OLOctavie Lunguya
Octavie Lunguya
JJJan Jacobs
Jan Jacobs